Long-Term Safety and Fat Reduction Maintenance Study
Treatments studied
This study checks if the effects of a previous fat-reducing treatment (CBL-514) last over time and if it remains safe. It's for people who already completed an earlier study with this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received at least one dose of CBL-514 or a placebo in the earlier parent study and finished its follow-up visit.
- You agree to keep your daily routines, like diet and exercise, fairly stable during the study.
- You are willing to sign a consent form and follow the study procedures.
- You cannot be taking any weight-loss medications (prescription or over-the-counter) or be in a weight-loss program.
- You must not have had or plan to have any other treatments that could affect the area being studied.
- If you are a woman who can become pregnant, you must use an approved birth control method and not be pregnant or breastfeeding. If you are a man, you must consistently use condoms during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called CBL-514 to reduce stubborn belly fat in people who are at a healthy weight but have moderate to severe abdominal fat. It may be an option if you've kept a stable lifestyle and are looking for a non-surgical approach.
This study tests whether CBL-514, an injectable medication, can safely reduce unwanted fat deposits under the skin in the abdomen. If it works, it could offer people a non-surgical option to improve the appearance of belly fat they're unhappy with.
This study tests whether CBL-514, an injection given under the skin, can safely reduce stubborn belly fat in people with normal to slightly elevated weight. Researchers will measure changes in abdominal fat using imaging and patient assessments.
This study tests a new injectable medication (CBL-514) designed to reduce stubborn fat under the skin in the abdominal area. Researchers will evaluate how well it works, its safety, and how patients tolerate it.
This study tests a new approach to help with weight loss and body fat reduction. It may be a good fit if you are an adult with a BMI in the overweight to moderately obese range and you are not currently using weight-loss medications.
This trial tests a new injection called MI226 to reduce belly fat. It is for people with noticeable belly fat who want to see if this treatment can help slim that area.
Hear when a new Subcutaneous Fat trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.